dormorna glp 1 Generic weight loss drugs to come off the market: What to know or prevent any disease. Oral GLP-1 Orforglipron Is Approved

If GLP-1 drugs reduce obesity, the logic goes, they should reduce downstream costs for diabetes care, cardiovascular events, joint replacements, sleep apnea treatment, and other expensive conditions

Jonathan Brugger is a board-certified ophthalmologist in Charleston, South Carolina Dr

Semaglutide also has an FDA label indication for reducing major adverse cardiovascular events in type 2 diabetic patients with cardiovascular disease

Compounded weight-loss drugs are a growing problem for state regulators Last August, North Carolina began covering some federal Food and Drug Administration-approved GLP-1s for obesity treatment among some populations

Kidney Function In patients with existing kidney issues, dehydration caused by nausea or diarrhea can worsen kidney function